NCT07190248View on ClinicalTrials.gov

A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

PHASE3RecruitingINTERVENTIONAL
Enrollment

675

Participants

Timeline

Start Date

October 8, 2025

Primary Completion Date

December 7, 2029

Study Completion Date

August 6, 2032

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

MK-1084

Administered as an oral tablet

BIOLOGICAL

Pembrolizumab (+) Berahyaluronidase alfa

Administered as a SC injection

DRUG

Pemetrexed

Administered as an IV Infusion

DRUG

Cisplatin

Administered as an IV Infusion

DRUG

Carboplatin

Administered as an IV Infusion

Trial Locations (2)

33010

RECRUITING

ME RIVNE REGIONAL ANTITUMOR CENTER ( Site 2517), Rivne

33140

RECRUITING

Mount Sinai Cancer Center ( Site 0137), Miami Beach

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT07190248 - A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) | Biotech Hunter | Biotech Hunter